PCM
TVRD

Pinz Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Pinz Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-228
Closed -$117K – 418
2021
Q2 		$117K Buy
+228
New +$144K 0.04% 186
2020
Q1 		– Sell
-245
Closed -$142K – 350
2019
Q4 		$142K Buy
+245
New +$172K 0.05% 113

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Pinz Capital Management's TVRD Position: Q3 2021 in Review

Pinz Capital Management sold out of Tvardi Therapeutics (TVRD) in Q3 2021, closing a stake of 228 shares — an estimated $117K sold.

Pinz Capital Management first reported a position in TVRD in Q4 2019 and held it in 2 quarters. The position peaked at $142K in Q4 2019. 168 funds tracked by Wall St. Rank hold TVRD as of Q3 2021.

  • Pinz Capital Management reported no remaining Tvardi Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Pinz Capital Management sold 228 Tvardi Therapeutics shares in Q3 2021, an estimated $117K.
  • Pinz Capital Management first reported a position in Tvardi Therapeutics in Q4 2019 and held it in 2 quarters.
  • Pinz Capital Management's Tvardi Therapeutics position peaked at $142K in Q4 2019.
  • 168 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.